Ca-AKG (Calcium Alpha-Ketoglutarate)
Ca-AKG is a calcium salt of alpha-ketoglutarate, a Krebs-cycle metabolite tied to epigenetic enzymes, inflammation signaling, and bone turnover. Mouse lifespan and frailty data from Shahmirzadi 2020 are strong, but human longevity evidence still rests on weak methylation-age data and a pending controlled trial.
Ca-AKG (Calcium Alpha-Ketoglutarate) scored 5.8 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient.
What It Is
Calcium alpha-ketoglutarate (Ca-AKG) is the calcium salt of alpha-ketoglutarate, a central intermediate in the Krebs cycle. AKG helps shuttle carbon and nitrogen through metabolism and also acts as a cofactor for epigenetic enzymes, especially TET enzymes and JmjC histone demethylases. In plain English: Ca-AKG sits at the intersection of energy production, amino-acid metabolism, inflammation signaling, and DNA/histone methylation control.
The reason longevity people care about Ca-AKG is mostly Shahmirzadi 2020, where aged mice fed Ca-AKG had longer lifespan and lower frailty, plus Chin 2014, where AKG extended C. elegans lifespan through ATP synthase and TOR signaling. The human story is much thinner. Filip 2007 supports a bone-turnover marker benefit in postmenopausal osteopenic women at a high 6 g/day AKG plus calcium dose. Demidenko 2021 reported a large methylation-age improvement in 42 Rejuvant users, but without a placebo arm and with vitamin co-administration.
That puts Ca-AKG in an unusual bucket: stronger than a random longevity supplement, weaker than a proven human healthspan intervention. It is cheap, easy, and mechanistically interesting. But the strongest claim, slowing human aging, still depends on the pending ABLE trial and future independent replication.
Terminology
- Ca-AKG: Calcium alpha-ketoglutarate. The calcium salt form used in most longevity products.
- AKG: Alpha-ketoglutarate, a Krebs-cycle intermediate involved in energy metabolism, nitrogen handling, and epigenetic enzyme function.
- Krebs cycle / TCA cycle: The mitochondrial pathway that converts nutrients into usable cellular energy intermediates.
- TET enzymes: DNA-demethylating enzymes that require AKG as a cofactor.
- JmjC demethylases: Histone-demethylating enzymes that require AKG as a cofactor.
- mTORC1 / TOR: Nutrient-sensing growth pathways involved in protein synthesis, autophagy, and aging biology.
- IL-10: An anti-inflammatory cytokine. In Shahmirzadi 2020, IL-10 signaling appeared necessary for the mouse lifespan and frailty benefits.
- CTX: C-terminal telopeptide of type I collagen, a blood marker of bone resorption.
- CAC: Coronary artery calcification, a CT-measured marker of calcified plaque burden.
- MESA: Multi-Ethnic Study of Atherosclerosis, the cohort behind the calcium-supplement caution in Anderson 2016.
- IDH: Isocitrate dehydrogenase, an enzyme near AKG metabolism. IDH mutations occur in some gliomas and AML.
- Rejuvant: Branded Ca-AKG formula from Ponce de Leon Health, paired with vitamin A or vitamin D3 depending on the product.
- ABLE: Alpha-ketoglutarate for Biological age reduction: a Longevity Evaluation, the controlled human trial registered as NCT05706389.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Generic calcium alpha-ketoglutarate powder or capsules | 1-2 g/day for longevity-oriented use; 6 g/day AKG plus calcium in the Filip bone-turnover protocol | 1-2 g/day AM fasted; some Blueprint-style users take 2 g/day |
| Oral | Branded Rejuvant Ca-AKG plus vitamin A or D3 | 1 g/day Ca-AKG plus vitamin A in the men's formula or vitamin D3 in the women's formula | Label dose daily for 6-12 months |
| Oral | AAKG (arginine alpha-ketoglutarate) | Not the Ca-AKG longevity form | Sports-supplement dosing varies widely |
Protocols
Conservative longevity protocol (default) Mixed
- Dose
- 1 g/day generic Ca-AKG oral
- Frequency
- AM fasted
- Duration
- Indefinite while monitoring total calcium intake
Pairing with vitamin K2 is common among longevity users, but direct Ca-AKG plus K2 outcome data do not exist. Avoid additional calcium supplements unless medically indicated.
Higher-dose longevity protocol Anecdotal
- Dose
- 2 g/day generic Ca-AKG oral
- Frequency
- AM fasted
- Duration
- Indefinite if tolerated
This doubles the calcium load to roughly 400 mg/day. Better suited for users with low dietary calcium than those already taking calcium or with vascular-calcification concerns.
Rejuvant label protocol Clinical
- Dose
- 1 g/day Ca-AKG plus formula-specific vitamin A or D3
- Frequency
- Daily
- Duration
- 6-12 months minimum
Based on [Demidenko 2021](https://pubmed.ncbi.nlm.nih.gov/34847066/), an uncontrolled retrospective study. Monitor retinol exposure if using the vitamin A formula.
Bone-turnover protocol (Filip derivative) Clinical
- Dose
- 6 g/day AKG plus calcium
- Frequency
- Daily
- Duration
- 24 weeks
Postmenopausal osteopenic women only. [Filip 2007](https://pubmed.ncbi.nlm.nih.gov/17896582/) supports CTX reduction, not proven fracture reduction. The calcium load is high enough to require clinician oversight.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 2.76
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.8 | 0.700 | |
| Breadth of Benefits | 15% | 3.2 | 0.480 | |
| Evidence Quality | 25% | 2.8 | 0.700 | |
| Speed of Onset | 10% | 2.0 | 0.200 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality Upside | 15% | 3.2 | 0.480 | |
| Total | 2.760 |
Upside Rationale
Ca-AKG (Calcium Alpha-Ketoglutarate)'s upside is a credible mechanistic bridge between metabolism, inflammation, bone turnover, and aging biology, but the useful read is narrower than the marketing version. Shahmirzadi 2020 supports the main direction of benefit, and Filip 2007 helps explain where that signal may matter in real use. Mechanistically, alpha-ketoglutarate sits in the Krebs cycle and intersects nutrient-sensing pathways, which makes the intervention plausible across several BioHarmony use cases. The strength is strongest when the goal matches bone markers, inflammatory markers, sleep, training response, or methylation panels. Ca-AKG (Calcium Alpha-Ketoglutarate) is weaker when the goal is vague optimization, because human lifespan, functional aging, and everyday performance data are not there yet. That makes Ca-AKG (Calcium Alpha-Ketoglutarate) a reasonable tool when the experiment is specific, measured, and time-bounded.
Efficacy (2.8/5.0). The best efficacy data are impressive but mostly nonhuman. Shahmirzadi 2020 reported longer lifespan and compressed morbidity in aged mice, with stronger female lifespan effects and lower frailty in both sexes. Chin 2014 showed AKG extended C. elegans lifespan through ATP synthase and TOR biology. Human efficacy is narrower: Filip 2007 found lower CTX bone-resorption markers in postmenopausal osteopenic women using 6 g/day AKG plus calcium for 24 weeks, while Demidenko 2021 reported methylation-age improvement without placebo control. Good signal. Not proven human longevity efficacy.
Breadth of benefits (3.2/5.0). Ca-AKG touches several aging-relevant systems: mitochondrial metabolism, amino-acid and nitrogen handling, DNA and histone demethylation, inflammation resolution, bone remodeling, frailty, and preclinical neuroplasticity. Navakkode 2025 adds APP/PS1 mouse evidence for hippocampal LTP rescue, especially in female mice. Niederegger 2026 supports burn-care interest in AKG/OKG for nitrogen balance and repair, but that is adjacent hospital nutrition. The breadth is real mechanistically. The human endpoint breadth is still thin.
Evidence quality (2.8/5.0). Evidence quality stays limited because there is no human longevity RCT result, no human Ca-AKG meta-analysis, and no major authority endorsement for healthy-aging use. The current stack is one strong mouse aging paper, one worm mechanism paper, one small human bone-turnover RCT, one uncontrolled Rejuvant methylation-age study, and newer animal or adjacent clinical-nutrition work. The audit also confirmed a material conflict-of-interest concern: Brian Kennedy is a major academic champion of the field and is linked to Ponce de Leon Health. That does not erase the data, but it does raise the replication bar.
Speed of onset (2.0/5.0). Ca-AKG is slow. Most users do not feel it acutely. Filip 2007 tracked bone-turnover markers over 24 weeks, with the practical signal living on a months-scale timeline. Demidenko 2021 reported methylation-age movement after months, not days. If Ca-AKG works for human aging, it likely works through slow metabolic, inflammatory, and epigenetic remodeling rather than a noticeable daily effect.
Durability (2.0/5.0). There are no good human washout data. The clean assumption is that Ca-AKG works only while the exposure continues, because age-related AKG decline, diet, inflammation, training status, and kidney function keep shaping baseline metabolism. ABLE includes follow-up that should help answer whether any biological-age changes persist after stopping. Until then, durability stays modest.
Bioindividuality (3.2/5.0). The best responder profile is older, inflamed, under-recovered, osteopenic, or biologically older than chronological age. Female mice showed stronger signals in Shahmirzadi 2020 and Navakkode 2025, but human sex-stratified evidence is missing. Young, fit users with low inflammation and strong mitochondrial function should expect smaller marginal benefit. Calcium status also matters: low-calcium users and high-calcium stackers are not the same risk profile.
Downside contribution: 1.95 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.8 | 0.540 | |
| Side Effect Profile | 15% | 1.5 | 0.225 | |
| Financial Cost | 5% | 2.2 | 0.110 | |
| Time/Effort Burden | 5% | 1.2 | 0.060 | |
| Opportunity Cost | 5% | 1.5 | 0.075 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.2 | 0.300 | |
| Total | 1.460 | |||
| Harm subtotal × 1.4 | 1.701 | |||
| Opportunity subtotal × 1.0 | 0.245 | |||
| Combined downside | 1.946 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.606 |
Downside Rationale
Ca-AKG (Calcium Alpha-Ketoglutarate)'s downside starts with evidence translation risk, not with a simple claim that Ca-AKG (Calcium Alpha-Ketoglutarate) is dangerous for everyone. Demidenko 2021 is the most useful caution anchor in the verified pool, and the broader tradeoff is that human lifespan, functional aging, and everyday performance data are not there yet. The risk also depends on context: calcium load, kidney history, medication context, and unclear long-term dosing can change the equation fast. That matters because a modest or uncertain upside has to clear a higher bar when the user has contraindications, poor tracking, or unrealistic expectations. In practice, Ca-AKG (Calcium Alpha-Ketoglutarate) deserves a narrow trial, conservative dosing or exposure, and a stop rule tied to bone markers, inflammatory markers, sleep, training response, or methylation panels.
Safety risk (1.8/5.0). Ca-AKG has no clear severe intrinsic toxicity signal in the available human and community evidence, but two cautions matter. First, each gram of Ca-AKG contributes roughly 200 mg elemental calcium. Anderson 2016 does not test Ca-AKG, but it does support caution around supplemental calcium and coronary artery calcification. Second, AKG is close to IDH and TET biology, so active IDH-mutant malignancy is a prudent avoidance zone until oncology-specific data clarify the direction. Severe CKD, hyperparathyroidism, and active vascular calcification also change the risk calculation.
Side effect profile (1.5/5.0). The common side effects are mild: loose stool, nausea, stomach discomfort, or lightheadedness in calcium-sensitive users. These tend to show up more at higher doses or with powder boluses. The old Riedel PMID in the v0.x report resolved to an unrelated renal-transplant hypertension paper, so it should not be used as safety proof. The safer framing is narrower: older hemodialysis literature such as the Karger Riedel record supports biochemical context in dialysis patients, not broad long-term safety in healthy adults.
Financial cost (2.2/5.0). Generic Ca-AKG is inexpensive, usually around $15-30/month at 1-2 g/day. Rejuvant is the outlier at roughly $150/month. Since Demidenko 2021 is uncontrolled and formula-confounded, the premium is hard to defend unless a user specifically wants that branded protocol. The score reflects generic access, not the premium brand.
Time / effort burden (1.2/5.0). Effort is low. One oral dose in the morning is the standard longevity-user pattern, and it stacks easily with creatine, taurine, glycine, NAD+ precursors, or breakfast supplements. The only real work is tracking total supplemental calcium, avoiding accidental retinol excess if using Rejuvant's vitamin A formula, and deciding whether you will measure biological age or bone markers before and after.
Opportunity cost (1.5/5.0). Ca-AKG rarely displaces better interventions because it is cheap, quick, and easy. The main opportunity cost is psychological: using an unproven longevity supplement can feel like progress while basics such as protein, resistance training, sleep, vitamin D status, and cardiometabolic risk go unmanaged. For bone health, Filip 2007 supports CTX movement, but Ca-AKG should not replace evidence-based osteoporosis evaluation or treatment.
Dependency / withdrawal (1.0/5.0). No dependency or withdrawal signal exists. Ca-AKG is a metabolic substrate class intervention, not a receptor-driving drug. Stopping should simply remove the extra AKG and calcium exposure. No craving, rebound, tolerance, or withdrawal syndrome has been reported in the evidence reviewed.
Reversibility (1.2/5.0). Ca-AKG itself is stop-anytime and reversible. The reason reversibility is not a perfect floor score is calcium load: if a high-dose calcium stack contributes to vascular calcification, that outcome is not quickly reversible. This is a dose and context issue, especially above 2 g/day Ca-AKG or when combined with separate calcium supplements.
Verdict
Ca-AKG (Calcium Alpha-Ketoglutarate) is a 5.8/10 fit for people treating aging biology as a tracked experiment, especially bone turnover, frailty, inflammation, or methylation-age curiosity, because the best signal is still preclinical longevity plus narrow human bone and methylation-age evidence. Shahmirzadi 2020 gives the strongest anchor, while Filip 2007 adds useful context without closing the case. The honest gap is simple: human lifespan, functional aging, and everyday performance data are not there yet. That puts Ca-AKG (Calcium Alpha-Ketoglutarate) in the tracked-experiment category, not the automatic-staple category. In practice, Ca-AKG (Calcium Alpha-Ketoglutarate) makes the most sense when you monitor bone markers, inflammatory markers, sleep, training response, or methylation panels and avoid treating Ca-AKG (Calcium Alpha-Ketoglutarate) like a proven anti-aging pill.
✅ Best for: Adults over 50 with elevated epigenetic age, especially if they are already measuring GrimAge, DunedinPACE, TruAge, or similar clocks and can repeat the same test after 4-7 months. Postmenopausal women with osteopenia who understand that Filip 2007 supports bone-turnover markers, not fracture prevention. Longevity stack builders who accept that Shahmirzadi 2020 is mouse data and Demidenko 2021 is uncontrolled. People with elevated inflammatory markers who want a low-cost experiment around the IL-10 and inflammaging pathway. Generic Ca-AKG users who can keep total supplemental calcium sane and do not need a felt daily effect.
❌ Avoid if: You have primary hyperparathyroidism, active coronary artery calcification, advanced atherosclerosis where supplemental calcium is discouraged, severe CKD with eGFR under 30, active IDH-mutant malignancy, pregnancy, or lactation. Avoid high-dose Ca-AKG if you already take calcium, eat a high-calcium fortified diet, or use Rejuvant plus high-retinol foods or cod liver oil. Skip it if you expect stimulant-like energy, visible anti-aging changes, or FDA-reviewed disease claims. Ca-AKG is a mechanism-trust supplement with promising animal data, thin human longevity data, and no major guideline endorsement for healthy-aging use.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Longevity / Lifespan: 7.0/10
Score: 7.0/10Ca-AKG (Calcium Alpha-Ketoglutarate)'s 7.0/10 longevity score starts with Shahmirzadi 2020, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: this verified source reported lifespan extension in aged mice, while this verified source supports a C. elegans longevity mechanism. Human lifespan data. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted longevity treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track harder biomarkers, frailty markers, and function, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Healthspan: 7.2/10
Score: 7.2/10On healthspan, Ca-AKG (Calcium Alpha-Ketoglutarate) deserves 7.2/10 because Filip 2007 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: this verified source reported lower frailty scores in aged mice. This is the cleanest healthspan signal, but human functional-aging translation remains pending. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted healthspan treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track daily function, recovery, labs, and resilience, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Methylation Support: 7.0/10
Score: 7.0/10The methylation case for Ca-AKG (Calcium Alpha-Ketoglutarate) is 7.0/10 because Shahmirzadi 2020 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: AKG is a cofactor for TET and JmjC demethylases, making methylation one of the strongest mechanistic fits. Controlled human methylation-clock evidence remains. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted methylation treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Bone / Joint Health: 7.4/10
Score: 7.4/10Ca-AKG (Calcium Alpha-Ketoglutarate)'s 7.4/10 bone-joint score starts with Filip 2007, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: this verified source found lower CTX bone-resorption markers at 24 weeks in postmenopausal women using 6 g/day AKG plus calcium. Fracture reduction. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted bone-joint treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track pain, range of motion, bone markers, and imaging when relevant, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Geriatric / Aging Population: 7.5/10
Score: 7.5/10On geriatric, Ca-AKG (Calcium Alpha-Ketoglutarate) deserves 7.5/10 because Filip 2007 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Cleanest responder profile is adults 50+ with lower endogenous AKG and higher frailty risk. this verified source directly targets aging biology, but. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted geriatric treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Anti-Inflammatory: 6.8/10
Score: 6.8/10The anti-inflammatory case for Ca-AKG (Calcium Alpha-Ketoglutarate) is 6.8/10 because Demidenko 2021 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: IL-10 dependence is supported by this verified source in mice, where IL-10 loss removed lifespan and frailty benefits. Human CRP and IL-6. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted anti-inflammatory treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Telomere / DNA Repair: 6.4/10
Score: 6.4/10The practical telomere-dna read on Ca-AKG (Calcium Alpha-Ketoglutarate) is 6.4/10 because Shahmirzadi 2020 anchors the strongest signal. The existing rationale points to this narrower claim: this verified source reported a methylation-age reduction in 42 Rejuvant users, but the study was uncontrolled, retrospective, vitamin-confounded, and brand-linked. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted telomere-dna treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Mitochondrial: 6.2/10
Score: 6.2/10On mitochondrial, Ca-AKG (Calcium Alpha-Ketoglutarate) deserves 6.2/10 because Demidenko 2021 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: AKG is a Krebs-cycle substrate, and this verified source links AKG to ATP synthase and TOR biology. Human mitochondrial endpoints are still. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted mitochondrial treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track training capacity, fatigue, and repeatable output, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Immune Function: 6.2/10
Score: 6.2/10For immune-function, Ca-AKG (Calcium Alpha-Ketoglutarate) lands at 6.2/10 because Shahmirzadi 2020 supports the strongest part of the claim. The existing rationale points to this narrower claim: IL-10 modulation in this verified source supports an immune-aging angle. Human immune-function outcomes are untested. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted immune-function treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track infection frequency, recovery time, and inflammatory markers, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Recovery / Repair: 6.0/10
Score: 6.0/10For recovery-repair, Ca-AKG (Calcium Alpha-Ketoglutarate) lands at 6.0/10 because Demidenko 2021 supports the strongest part of the claim. The existing rationale points to this narrower claim: Mechanistic support through TCA substrate and nitrogen metabolism, plus Nick's personal performance note. Controlled exercise-recovery RCTs are missing. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted recovery-repair treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Cellular Senescence: 5.8/10
Score: 5.8/10A 5.8/10 for cellular-senescence fits Ca-AKG (Calcium Alpha-Ketoglutarate) because Demidenko 2021 supports direction more than certainty. The existing rationale points to this narrower claim: Frailty reduction suggests downstream aging-biology relevance, but there is no direct human senescence-marker trial. Treat as mechanism-adjacent, not proven. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted cellular-senescence treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Memory: 5.8/10
Score: 5.8/10On memory, Ca-AKG (Calcium Alpha-Ketoglutarate) deserves 5.8/10 because Shahmirzadi 2020 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Preclinical hippocampal LTP and synaptic tagging signal from this verified source is interesting but still mouse-only. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted memory treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Neuroplasticity: 5.8/10
Score: 5.8/10A 5.8/10 for neuroplasticity fits Ca-AKG (Calcium Alpha-Ketoglutarate) because Filip 2007 supports direction more than certainty. The existing rationale points to this narrower claim: JmjC histone-demethylase cofactor biology is neuroplasticity-adjacent, and this verified source adds preclinical support. Human data are absent. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted neuroplasticity treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Endurance / Cardio: 5.8/10
Score: 5.8/10The practical endurance-cardio read on Ca-AKG (Calcium Alpha-Ketoglutarate) is 5.8/10 because Filip 2007 anchors the strongest signal. The existing rationale points to this narrower claim: Plausible ATP-cycle rationale and performance note, but no controlled endurance trial in trained athletes. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted endurance-cardio treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track heart rate, pace, blood pressure, and recovery, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Cognition / Focus: 5.6/10
Score: 5.6/10Ca-AKG (Calcium Alpha-Ketoglutarate)'s 5.6/10 cognition-focus score starts with Demidenko 2021, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: this verified source supports hippocampal LTP rescue in APP/PS1 mice, especially females. No human cognition trial exists. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted cognition-focus treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Neuroprotection: 5.6/10
Score: 5.6/10The practical neuroprotection read on Ca-AKG (Calcium Alpha-Ketoglutarate) is 5.6/10 because Demidenko 2021 anchors the strongest signal. The existing rationale points to this narrower claim: this verified source showed AKG and Ca-AKG rescued synaptic plasticity deficits in APP/PS1 mice. This is not human neuroprotection evidence. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted neuroprotection treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Antioxidant / Oxidative Stress: 5.5/10
Score: 5.5/10For antioxidant, Ca-AKG (Calcium Alpha-Ketoglutarate) lands at 5.5/10 because Filip 2007 supports the strongest part of the claim. The existing rationale points to this narrower claim: Indirect via TCA substrate support and redox cycling; no direct antioxidant-marker RCTs in humans. Animal data are supportive but not enough to. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted antioxidant treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Autophagy: 5.5/10
Score: 5.5/10Ca-AKG (Calcium Alpha-Ketoglutarate) earns 5.5/10 for autophagy because Filip 2007 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: this verified source connected AKG to ATP synthase, TOR signaling, and autophagy in C. elegans and cells. Human autophagy-flux data are absent. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted autophagy treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Strength / Power: 5.5/10
Score: 5.5/10On strength-power, Ca-AKG (Calcium Alpha-Ketoglutarate) deserves 5.5/10 because Demidenko 2021 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Indirect support from frailty and muscle-health mechanisms, but no trained-athlete strength or power RCT. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted strength-power treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track body composition, strength, soreness, and training logs, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Energy / Fatigue: 5.4/10
Score: 5.4/10A 5.4/10 for energy fits Ca-AKG (Calcium Alpha-Ketoglutarate) because Shahmirzadi 2020 supports direction more than certainty. The existing rationale points to this narrower claim: Mechanistic energy-metabolism rationale exists, and Nick notes subjective performance benefit, but there are no controlled human energy endpoints. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted energy treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Metabolic Health: 5.4/10
Score: 5.4/10The practical metabolic-health read on Ca-AKG (Calcium Alpha-Ketoglutarate) is 5.4/10 because Filip 2007 anchors the strongest signal. The existing rationale points to this narrower claim: No direct human metabolic-health RCT. AKG's central metabolism role is relevant but does not yet translate into glucose, lipid, or insulin evidence. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted metabolic-health treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track fasting glucose, waist, energy, and appetite, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Skin / Beauty: 5.4/10
Score: 5.4/10A 5.4/10 for skin-beauty fits Ca-AKG (Calcium Alpha-Ketoglutarate) because Demidenko 2021 supports direction more than certainty. The existing rationale points to this narrower claim: Mechanism via fibroblast epigenetic remodeling is possible, but human skin evidence is anecdotal only. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted skin-beauty treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track photos, shedding, skin quality, and time to visible change, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Kidney Function: 5.4/10
Score: 5.4/10The kidney-function case for Ca-AKG (Calcium Alpha-Ketoglutarate) is 5.4/10 because Filip 2007 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: the cited study hemodialysis literature supports biochemical context in dialysis patients, but the prior supplied PMID was unrelated. No general kidney-function benefit. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted kidney-function treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Blood Sugar / Glycemic Control: 5.2/10
Score: 5.2/10Ca-AKG (Calcium Alpha-Ketoglutarate) earns 5.2/10 for blood-sugar because Demidenko 2021 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: No direct human glucose RCTs. Keep near neutral until fasting glucose, insulin, HbA1c, or CGM outcomes are tested. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted blood-sugar treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track fasting glucose, post-meal response, and energy stability, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Cardiovascular: 5.2/10
Score: 5.2/10The cardiovascular case for Ca-AKG (Calcium Alpha-Ketoglutarate) is 5.2/10 because Filip 2007 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Mechanism is mostly neutral, while calcium load creates a dose-dependent caution. this verified source is calcium-supplement evidence, not Ca-AKG-specific harm. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted cardiovascular treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track heart rate, pace, blood pressure, and recovery, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Stress / Resilience: 5.2/10
Score: 5.2/10The stress-resilience case for Ca-AKG (Calcium Alpha-Ketoglutarate) is 5.2/10 because Demidenko 2021 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Indirect via inflammaging and IL-10 signaling in this verified source, but no human stress-resilience endpoints. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted stress-resilience treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Muscle Growth / Hypertrophy: 5.2/10
Score: 5.2/10A 5.2/10 for muscle-growth fits Ca-AKG (Calcium Alpha-Ketoglutarate) because Shahmirzadi 2020 supports direction more than certainty. The existing rationale points to this narrower claim: No hypertrophy RCT data. Nitrogen-balance and burn-care literature is adjacent, not proof of muscle growth in healthy adults. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted muscle-growth treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track body composition, strength, soreness, and training logs, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Sleep Quality: 5.0/10
Score: 5.0/10Ca-AKG (Calcium Alpha-Ketoglutarate) earns 5.0/10 for sleep-quality because Shahmirzadi 2020 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: No direct Ca-AKG sleep trial or consistent community signal. Keep neutral unless ABLE or later human studies include sleep outcomes. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted sleep-quality treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track sleep latency, awakenings, and next-day steadiness, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Stem Cell Support: 5.0/10
Score: 5.0/10For stem-cell, Ca-AKG (Calcium Alpha-Ketoglutarate) lands at 5.0/10 because Demidenko 2021 supports the strongest part of the claim. The existing rationale points to this narrower claim: No direct stem-cell data. AKG's epigenetic-enzyme role is relevant to cell state, but not enough for a stem-cell use-case claim. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted stem-cell treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Liver / Detoxification: 5.0/10
Score: 5.0/10Ca-AKG (Calcium Alpha-Ketoglutarate)'s 5.0/10 liver-detox score starts with Filip 2007, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: No direct liver-detox evidence. AKG participates in nitrogen and amino-acid metabolism, but that does not equal a liver-detox outcome. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted liver-detox treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Body Composition / Fat Loss: 5.0/10
Score: 5.0/10For body-composition, Ca-AKG (Calcium Alpha-Ketoglutarate) lands at 5.0/10 because Shahmirzadi 2020 supports the strongest part of the claim. The existing rationale points to this narrower claim: No direct body-composition evidence for Ca-AKG. Any effect would likely be indirect through frailty, training capacity, or nitrogen metabolism. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted body-composition treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track body composition, strength, soreness, and training logs, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Mood / Emotional Regulation: 5.0/10
Score: 5.0/10Ca-AKG (Calcium Alpha-Ketoglutarate) earns 5.0/10 for mood because Shahmirzadi 2020 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: No mood signal in the literature or community reports strong enough to separate Ca-AKG from placebo. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted mood treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track mood score, irritability, and stress recovery, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Anxiety: 5.0/10
Score: 5.0/10For anxiety, Ca-AKG (Calcium Alpha-Ketoglutarate) lands at 5.0/10 because Filip 2007 supports the strongest part of the claim. The existing rationale points to this narrower claim: No direct evidence. Any anti-inflammatory mood pathway remains speculative until tested in humans. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted anxiety treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Hormonal / Endocrine: 5.0/10
Score: 5.0/10Ca-AKG (Calcium Alpha-Ketoglutarate)'s 5.0/10 hormonal score starts with Shahmirzadi 2020, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: No direct hormonal data. Current evidence does not support claims around testosterone, thyroid, estrogen, or adrenal hormones. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted hormonal treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track lab work, libido, sleep, and mood, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Hair / Nail Health: 5.0/10
Score: 5.0/10The practical hair-nail read on Ca-AKG (Calcium Alpha-Ketoglutarate) is 5.0/10 because Shahmirzadi 2020 anchors the strongest signal. The existing rationale points to this narrower claim: No hair or nail evidence. Keep neutral unless dermatology trials emerge. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted hair-nail treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track photos, shedding, skin quality, and time to visible change, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Wound Healing: 5.0/10
Score: 5.0/10Ca-AKG (Calcium Alpha-Ketoglutarate) earns 5.0/10 for wound-healing because Filip 2007 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: No direct consumer Ca-AKG wound-healing evidence. Burn-care OKG and AKG literature is adjacent, heterogeneous, and not a longevity-supplement proof. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted wound-healing treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Injury Recovery: 5.0/10
Score: 5.0/10The injury-recovery case for Ca-AKG (Calcium Alpha-Ketoglutarate) is 5.0/10 because Shahmirzadi 2020 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: No direct injury-recovery evidence for consumer Ca-AKG. Burn-care and hospital nutrition literature should not be overextended. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted injury-recovery treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
VO2 Max: 5.0/10
Score: 5.0/10Ca-AKG (Calcium Alpha-Ketoglutarate) earns 5.0/10 for vo2-max because Demidenko 2021 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: No direct VO2 max data. Keep neutral until cardiorespiratory trials exist. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted vo2-max treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Chronic Pain Management: 5.0/10
Score: 5.0/10Ca-AKG (Calcium Alpha-Ketoglutarate)'s 5.0/10 chronic-pain score starts with Demidenko 2021, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: Anti-inflammatory mechanism is chronic-pain-adjacent, but there are no direct pain RCTs. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate) a targeted chronic-pain treatment. The report's best evidence is mostly mechanism, animal data, and narrow human markers rather than direct outcome trials, so the score is directional rather than settled. Track pain score, stiffness, mobility, and medication need, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
| Use Case | Score | Summary |
|---|---|---|
| ⚖️ Depression | 4.8 | No depression evidence. Ca-AKG should not be positioned as a mood intervention. |
| ⚖️ HRV / Vagal Tone / Autonomic Balance | 4.8 | No direct HRV or vagal-tone data. Do not infer autonomic benefit from general metabolic support. |
| ⚖️ Flexibility / Mobility | 4.8 | No direct flexibility, mobility, or range-of-motion data. Frailty improvement in mice is too indirect. |
| ⚖️ Gut Health / Microbiome | 4.8 | No direct gut-health evidence. AKG may affect intestinal metabolism in animals, but consumer Ca-AKG human evidence is absent. |
| ○ Sleep Architecture (Deep/REM) | 4.5 | No direct evidence on REM, deep sleep, sleep latency, or sleep efficiency. Score stays below neutral because the mechanism does not map cleanly to sleep architecture. |
| ○ Circadian Rhythm / Chronobiology | 4.5 | No direct circadian data. AKG connects to metabolism and nutrient sensing, but there is no human circadian endpoint or timing study. |
| ○ Heavy Metal / Toxin Burden | 4.5 | No direct evidence for heavy-metal clearance, chelation, or clinical detoxification. Use established detoxification protocols instead. |
| ○ Nerve Regeneration | 4.5 | No direct nerve-regeneration evidence. Keep below neutral until peripheral nerve or neuropathy trials exist. |
| ○ Traumatic Brain Injury | 4.5 | No direct traumatic-brain-injury evidence. Do not borrow from unrelated mitochondrial or neuroplasticity interventions. |
| ○ Flow State / Peak Mental Performance | 4.5 | No direct evidence for flow state, reaction speed, or acute mental-performance state changes. |
| ○ Creativity / Divergent Thinking | 4.5 | No creativity evidence. Mechanistic brain-aging logic is too indirect for this use case. |
| ○ Reaction Time / Coordination | 4.5 | No direct reaction-time trial or sports-cognition endpoint. Score remains below neutral. |
| ○ Libido / Sexual Health | 4.5 | No direct libido evidence. Any performance benefit does not translate into sexual-function evidence. |
| ○ Fertility (Male) | 4.5 | No direct male-fertility data for Ca-AKG. Do not extrapolate from unrelated AKG salts or mitochondrial fertility studies. |
| ○ Fertility (Female) | 4.5 | No direct female-fertility evidence. Avoid in pregnancy and lactation because safety data are insufficient. |
| ○ Pediatric Use | 4.5 | No pediatric Ca-AKG evidence. Pediatric use should be avoided outside clinician-directed metabolic or nutrition contexts. |
| ○ Respiratory | 4.5 | No direct respiratory evidence. Do not infer benefit from general mitochondrial or anti-inflammatory mechanisms. |
| ○ Eye / Vision Health | 4.5 | No direct eye or vision evidence for Ca-AKG. Avoid borrowing from unrelated photobiomodulation or mitochondrial eye studies. |
| ○ Lymphatic / Drainage | 4.5 | No direct lymphatic evidence. |
| ○ Cold / Heat Tolerance / Hormesis | 4.5 | No evidence for cold or heat tolerance. Any stress-resilience claim remains indirect. |
| ○ Acute Pain Relief | 4.5 | No acute-pain evidence. Ca-AKG is not an analgesic. |
| ○ Social Bonding / Empathy | 4.0 | Not applicable. No oxytocin, social behavior, or affiliative-behavior evidence. |
| ○ Spiritual / Consciousness Expansion | 4.0 | Not applicable. No evidence for consciousness, meditation depth, or spiritual-state changes. |
| ○ Hearing / Auditory | 4.0 | No hearing or auditory evidence. |
| ○ Dental / Oral Health | 4.0 | No dental or oral-health evidence. |
| ○ Electromagnetic / Frequency Therapy | 4.0 | Not applicable. Ca-AKG is a supplement, not an electromagnetic or frequency intervention. |
Frequently Asked Questions
What is calcium alpha-ketoglutarate and how does it work?
Ca-AKG is the calcium salt of alpha-ketoglutarate, a Krebs-cycle metabolite and cofactor for TET DNA demethylases and JmjC histone demethylases. Chin 2014 showed AKG extended C. elegans lifespan by interacting with ATP synthase and TOR signaling, while Shahmirzadi 2020 linked Ca-AKG to lower inflammation and frailty in aged mice. That mechanism is promising, but human longevity proof is still pending.
Does Ca-AKG really reduce biological age?
Maybe, but the current human claim is weak. Demidenko 2021 reported a large TruAge biological-age reduction after months on Rejuvant in 42 users, but it was retrospective, uncontrolled, brand-linked, and included vitamin A or D3 co-administration. The important next test is ABLE, a placebo-controlled Ca-AKG trial using several epigenetic clocks. Until that reads out, biological-age reversal should be treated as unproven.
Is Rejuvant worth the premium over generic Ca-AKG?
Probably not for most users. Generic Ca-AKG powder or capsules usually cost a fraction of Rejuvant and deliver the same core molecule. The premium rests mainly on Demidenko 2021, which was not placebo-controlled and used a branded formula with vitamin A or D3. If you use Rejuvant, track retinol exposure from cod liver oil, organ meats, and multivitamins. If you want the molecule, generic Ca-AKG is the cleaner value bet.
What are the side effects of Ca-AKG?
Most users report either nothing or mild digestive effects such as loose stool or nausea at higher doses. The bigger practical issue is calcium load: each gram of Ca-AKG contributes roughly 200 mg elemental calcium. Anderson 2016 found calcium supplement use was associated with more coronary artery calcification in MESA, but that was not a Ca-AKG trial. At 1 g/day the load is modest. At 2 g/day or higher, stop stacking extra calcium casually.
Who should not take Ca-AKG?
Avoid Ca-AKG if you have primary hyperparathyroidism, severe CKD with eGFR under 30, active coronary artery calcification, advanced atherosclerosis where supplemental calcium is discouraged, pregnancy, or lactation. Active IDH-mutant malignancy, including some gliomas and AML, is a precaution because AKG sits near IDH and TET biology. That is a mechanistic caution, not a documented supplementation-harm finding. If you have cancer history or kidney disease, treat Ca-AKG as clinician-review territory.
How long before Ca-AKG works?
Most users should not expect a noticeable same-day effect. Ca-AKG is a months-scale supplement. Filip 2007 tracked bone turnover over 24 weeks in postmenopausal osteopenic women, while Demidenko 2021 reported methylation-age changes after months of Rejuvant use. If you need something you can feel, this is the wrong tool. If you use it, measure before and after with the same biomarker method.
Can I take Ca-AKG with other longevity supplements?
Usually yes. Ca-AKG stacks cleanly with NAD+ precursors, taurine, glycine, creatine, exercise, and protein adequacy. The main constraint is calcium math, not AKG itself. Avoid combining Ca-AKG with separate high-dose calcium unless a clinician wants that. Many longevity users add vitamin K2, but no Ca-AKG plus K2 outcome trial proves that strategy. Also avoid duplicating the Rejuvant vitamin A formula with high-retinol diets or cod liver oil.
Is Ca-AKG different from AAKG?
Yes. Ca-AKG and AAKG are not interchangeable. Calcium alpha-ketoglutarate is the form discussed in Shahmirzadi 2020 and most longevity marketing. Arginine alpha-ketoglutarate is a sports-supplement salt used mostly for nitric-oxide and pump claims. If a study, product, or protocol says Ca-AKG or Rejuvant, do not substitute AAKG and assume the same evidence applies. The salt form changes the practical evidence base.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| ABLE RCT confirms at least 2-year epigenetic-age reduction | Evidence 2.8 to 4.0; Efficacy 2.8 to 3.5 | 7.1 / 10 💪 Strong recommend |
| ABLE RCT is null on composite epigenetic endpoint | Evidence 2.8 to 2.0; Efficacy 2.8 to 2.3 | 5.6 / 10 👍 Worth trying |
| Independent RCT confirms CRP or IL-6 reduction in humans | Evidence 2.8 to 3.5; Breadth 3.2 to 3.8 | 6.8 / 10 💪 Strong recommend |
| Head-to-head trial against calcium citrate placebo shows benefit is calcium, not AKG | Efficacy 2.8 to 2.0; Evidence 2.8 to 2.3 | 5.3 / 10 👍 Worth trying |
| Large observational study confirms vascular-calcification signal at more than 2 g/day Ca-AKG | Safety 1.8 to 2.6 | 5.7 / 10 👍 Worth trying |
| Kennedy and Ponce de Leon concern is resolved by fully independent replication | Evidence 2.8 to 3.6 | 6.5 / 10 💪 Strong recommend |
Key Evidence Sources
- Shahmirzadi AA et al. 2020 - Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice, Cell Metabolism. Mouse Ca-AKG lifespan and frailty study; supports preclinical longevity and healthspan direction, not human longevity efficacy.
- Filip R et al. 2007 - Alpha-ketoglutarate decreases serum CTX in postmenopausal women with osteopenia, Journal of Bone and Mineral Metabolism. Human 24-week DBRCT in 76 postmenopausal osteopenic women; supports bone-turnover marker reduction, not fracture reduction.
- Demidenko O et al. 2021 - Rejuvant, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, Aging. Uncontrolled retrospective 42-user Rejuvant methylation-age study; cite as Demidenko, not Filip.
- Navakkode S et al. 2025 - Alpha-Ketoglutarate Ameliorates Synaptic Plasticity Deficits in APP/PS1 Mice Model of Alzheimer's Disease. Preclinical APP/PS1 mouse LTP and synaptic plasticity signal; not human cognition evidence.
- Anderson JJB et al. 2016 - Calcium Intake From Diet and Supplements and Risk of Coronary Artery Calcification, MESA. Adjacent calcium-supplement caution; not a Ca-AKG-specific cardiovascular harm study.
- Chin RM et al. 2014 - The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR, Nature. C. elegans and cell mechanism paper; correct PMID for the Chin AKG lifespan paper.
- Niederegger H et al. 2026 - Metabolic and Immunomodulatory Effects of alpha-Ketoglutarate in Burn Injuries: A Systematic Review, Journal of Burn Care & Research. Burn-care AKG/OKG systematic review; adjacent hospital-nutrition evidence, heterogeneous and not consumer longevity proof.
- Xu Y et al. 2024 - Impact of Alpha-Ketoglutarate on Skeletal Muscle Health and Exercise Performance: A Narrative Review, Nutrients. Narrative review across muscle health and performance mechanisms; not an RCT or meta-analysis.
- Wang J et al. 2025 - Effects of alpha-Ketoglutarate Peripartum Supplementation in Dairy Cows, Animals. Animal feeding study; supports veterinary immunometabolic direction only.
- Sun Y et al. 2025 - Effects of Alpha-Ketoglutarate Supplementation on Growth Performance, Diarrhea Incidence, Plasma Amino Acid, and Nutrient Digestibility in Weaned Piglets, Animals. Piglet AKG feeding study; animal gut and amino-acid context only.
- Sun Y et al. 2025 - Effects of Dietary Alpha-Ketoglutarate Supplementation on Diarrhea Incidence and Nutrient Digestibility in Weaned Piglets Fed Low-Protein Diets, Veterinary Sciences. Low-protein piglet diet study; animal nutrition evidence only.
- Riedel E et al. 1996 - Ketoglutarate Application in Hemodialysis Patients Improves Amino Acid Metabolism, Nephron. Hemodialysis biochemical context; prior supplied PMID was unrelated and is not used.
- Lund University record for Filip R et al. 2007 - Alpha-ketoglutarate decreases serum CTX in postmenopausal women with osteopenia. Publisher-adjacent institutional title confirmation for the Filip bone-turnover paper.
- ABLE trial - Alpha-Ketoglutarate for Biological age reduction: a Longevity Evaluation, NCT05706389. Key pending placebo-controlled human biological-age trial.
- ScienceDirect page for Shahmirzadi AA et al. 2020 - Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice. Journal-page confirmation for the mouse lifespan and morbidity-compression study.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Shahmirzadi 2020, Filip 2007, Demidenko 2021, Navakkode 2025, Chin 2014, Niederegger 2026
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Krebs 1937, Riedel 1996, Filip 2007, Chin 2014
Traditional Medicine Systems
Confidence: Low
Citations: Li Shizhen 1596
Holistic Evidence for Ca-AKG (Calcium Alpha-Ketoglutarate)
Modern science, clinical-nutrition history, and traditional food practice converge on a broad idea: nitrogen handling, mineral status, and energy metabolism matter during aging, repair, and recovery. They diverge sharply on Ca-AKG itself. The isolated supplement has preclinical longevity promise and limited human signals, while history supports clinical nutrition uses and tradition supports broader food patterns rather than this molecule. That keeps the score in worth-trying territory until controlled human aging data arrive.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Biological Age Baseline (pre-protocol)
- Biological Age Delta Post | Expected Down
- Calcium During | Expected Stable
- Creatinine During | Expected Stable
- eGFR During | Expected Stable
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Body During | Expected Up | Secondary
- Drive During | Expected Stable | Tertiary
Subjective Signals (Daily Voice Card)
- Exercise Recovery Scale 1-5 | During | Expected Up
- Bowel Regularity Scale 1-5 | During | Expected Watch
- Morning Energy Scale 1-5 | During | Expected Up
Red Flags: Stop and Consult
- Kidney stone symptoms
- Persistent constipation or GI distress
Other interventions for Longevity
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.760 − 0.606 = 1.154
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.154 / 5) × 5 = 6.2 / 10
Further learning
4 Best AKG Supplements: Benefits, Dosage, & Review of Alpha-Ketoglutarate
Alpha-ketoglutarate is a natural longevity nutrient used to extend healthspan, enhance athletic performance, and boost overall wellbeing.
Control Your Genetics: A Deep Dive Into Epigenetic Testing, Biological Age Clocks, Longevity Protocols, Therapies & Supplementation
What if aging was optional? Or that you could actually have control over your genetics or genetic dispositions to diseases and the like. In…
